| Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis R Gilmore, P Hilley, A Srinivasan, M Choy, P De Cruz Journal of Crohn's and Colitis 16 (1), 166-168, 2022 | 40 | 2022 |
| a practical approach to the clinical management of NSAID enteropathy A Srinivasan, P De Cruz Scandinavian journal of gastroenterology 52 (9), 941-947, 2017 | 37 | 2017 |
| Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn’s disease A Srinivasan, A Vasudevan, A McFarlane, MP Sparrow, PR Gibson, ... Journal of Crohn's and Colitis 12 (3), 280-288, 2018 | 34 | 2018 |
| Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience H Ibraheim, MA Samaan, A Srinivasan, O Brain, J Digby-Bell, PM Irving, ... Annals of Gastroenterology 33 (2), 170, 2020 | 28 | 2020 |
| Establishment of human retinal pigment epithelial cell lines by oncogenes. K Dutt, M Scott, M Del Monte, N Agarwal, P Sternberg, SK Srivastava, ... Oncogene 5 (2), 195-200, 1990 | 27 | 1990 |
| Higher anti-tumor necrosis factor-α levels correlate with improved radiologic outcomes in Crohn’s perianal fistulas M De Gregorio, T Lee, K Krishnaprasad, G Amos, YK An, ... Clinical Gastroenterology and Hepatology 20 (6), 1306-1314, 2022 | 24 | 2022 |
| Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study C Haifer, A Srinivasan, YK An, S Picardo, D van Langenberg, S Menon, ... Medical Journal of Australia 214 (3), 128-133, 2021 | 20 | 2021 |
| Vedolizumab for ulcerative colitis: real world outcomes from a multicenter observational cohort of Australia and Oxford SSR Pulusu, A Srinivasan, K Krishnaprasad, D Cheng, J Begun, C Keung, ... World journal of gastroenterology 26 (30), 4428, 2020 | 19 | 2020 |
| A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease A Srinivasan, DR van Langenberg, RD Little, MP Sparrow, P De Cruz, ... Alimentary pharmacology & therapeutics 51 (12), 1342-1352, 2020 | 16 | 2020 |
| Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease A Srinivasan, R Gilmore, D van Langenberg, P De Cruz Therapeutic Advances in Gastroenterology 15, 17562848211070940, 2022 | 11 | 2022 |
| Impact of providing patients with copies of their medical correspondence: a randomised controlled study C Fenton, A Al‐Ani, A Trinh, A Srinivasan, K Marion, G Hebbard Internal Medicine Journal 47 (1), 68-75, 2017 | 10 | 2017 |
| Tofacitinib is safe and effective when used in combination with infliximab for the management of refractory ulcerative colitis R Gilmore, P Hilley, A Srinivasan, MC Choy, JA Grace, P De Cruz Clinical Gastroenterology and Hepatology 19 (6), 1302-1303, 2021 | 9 | 2021 |
| The nocebo effect in a non-medical switching program from originator to biosimilar infliximab in inflammatory bowel disease K Dutt, A Srinivasan, D Van Langenberg BioDrugs 36 (5), 639-644, 2022 | 8 | 2022 |
| Outcomes out to 12 months after sequential use of high‐dose tofacitinib following infliximab in acute severe ulcerative colitis A Eqbal, P Hilley, M Choy, A Srinivasan, P de Cruz Internal Medicine Journal 53 (8), 1497-1500, 2023 | 6 | 2023 |
| Ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval A Srinivasan, P De Cruz, DR van Langenberg Aliment Pharmacol Ther 52 (3), 564-5, 2020 | 5 | 2020 |
| Treat to target in Crohn’s disease: a practical guide for clinicians AR Srinivasan World Journal of Gastroenterology 30 (1), 50, 2024 | 4 | 2024 |
| Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis P Hilley, R Gilmore, A Srinivasan, M Choy, P De Cruz Inflammatory bowel diseases 27 (9), e105-e106, 2021 | 4 | 2021 |
| Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel … C Haifer, A Srinivasan, S Menon, Y An, S Picardo, D Van Langenberg, ... Journal of Gastroenterology and Hepatology 34, 155-156, 2019 | 4 | 2019 |
| The role of intestinal ultrasound during pregnancy in patients with inflammatory bowel disease B Andrew, A Vasudevan, A Srinivasan Official journal of the American College of Gastroenterology| ACG 118 (11 …, 2023 | 3 | 2023 |
| Using Ustekinumab to Treat Crohn’s Disease–Related Orofacial Granulomatosis: Two Birds, One Stone R Gilmore, CFD Li Wai Suen, T Elliott, P De Cruz, A Srinivasan Inflammatory bowel diseases 26 (8), e79-e80, 2020 | 3 | 2020 |
